第692号委员会意见:妊娠期及产后急性发作严重高血压的紧急治疗
该委员会意见指出,妊娠期、产程中或产后可出现急性发作的严重收缩期高血压、严重舒张期高血压或两者兼有,需紧急降压治疗。实施标准化、循证临床指南已被证明可减少不良母体结局。机构应建立机制确保患者出现高血压急症时能及时给药。一线药物应在确诊严重高血压后30–60分钟内尽快启动,以降低孕产妇卒中风险。静脉拉贝洛尔和肼屈嗪长期被视为一线药物,口服速释硝苯地平也可考虑作为一线治疗,尤其在没有静脉通路时。若连续适当剂量静脉推注拉贝洛尔、肼屈嗪或口服速释硝苯地平未能缓解,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
要点
- 妊娠期或产后急性发作严重高血压需紧急降压,确诊后30–60分钟内尽快启动一线药物治疗以降低孕产妇卒中风险。
- 静脉拉贝洛尔和肼屈嗪长期被视为妊娠期及产后急性发作严重高血压的一线药物。
- 口服速释硝苯地平也可考虑作为一线治疗,尤其在没有静脉通路时。
- 连续适当剂量的一线药物未能缓解严重高血压时,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
- 实施标准化、循证临床指南已被证明可减少不良母体结局,机构应建立及时给药的机制。
适用人群与场景
- 妊娠期、产程中或产后的孕妇或产后女性,出现急性发作的严重收缩期高血压、严重舒张期高血压或两者兼有。
处置流程与药物剂量
- 确诊严重高血压后30–60分钟内尽快启动一线药物治疗以降低孕产妇卒中风险。
- 静脉拉贝洛尔和肼屈嗪长期被视为一线药物。
- 口服速释硝苯地平也可考虑作为一线治疗,尤其在没有静脉通路时。
- 连续适当剂量静脉推注拉贝洛尔、肼屈嗪或口服速释硝苯地平未能缓解时,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
研究设计与关键结果
- 实施标准化、循证临床指南已被证明可减少子痫前期和子痫患者的不良母体结局。
证据类型、等级与局限
- 证据类型:委员会意见(指南/共识)。
- 局限:原文未报告局限性。
对床旁实践的改变
- 机构应建立机制,确保患者出现高血压急症时能及时给药。
- 对妊娠期或产后急性发作严重高血压,应在确诊后30–60分钟内尽快启动一线降压治疗。
- 无静脉通路时,口服速释硝苯地平也可考虑作为一线治疗。
- 一线药物连续适当剂量未能缓解时,建议紧急请麻醉科、母胎医学专科或重症监护专科会诊讨论二线干预。
指南或共识出处
- Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period(Obstet Gynecol)
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Acute-onset, severe systolic hypertension; severe diastolic hypertension; or both can occur during the prenatal, intrapartum, or postpartum periods. Pregnant women or women in the postpartum period with acute-onset, severe systolic hypertension; severe diastolic hypertension; or both require urgent antihypertensive therapy. Introducing standardized, evidence-based clinical guidelines for the management of patients with preeclampsia and eclampsia has been demonstrated to reduce the incidence of adverse maternal outcomes. Individuals and institutions should have mechanisms in place to initiate the prompt administration of medication when a patient presents with a hypertensive emergency. Treatment with first-line agents should be expeditious and occur as soon as possible within 30-60 minutes of confirmed severe hypertension to reduce the risk of maternal stroke. Intravenous labetalol and hydralazine have long been considered first-line medications for the management of acute-onset, severe hypertension in pregnant women and women in the postpartum period. Although relatively less information currently exists for the use of calcium channel blockers for this clinical indication, the available evidence suggests that immediate release oral nifedipine also may be considered as a first-line therapy, particularly when intravenous access is not available. In the rare circumstance that intravenous bolus labetalol, hydralazine, or immediate release oral nifedipine fails to relieve acute-onset, severe hypertension and is given in successive appropriate doses, emergent consultation with an anesthesiologist, maternal-fetal medicine subspecialist, or critical care subspecialist to discuss second-line intervention is recommended.
参考来源
- Committee Opinion No. 692: Emergent Therapy for Acute-Onset, Severe Hypertension During Pregnancy and the Postpartum Period. Obstet Gynecol. 2017. PMID: 28333820. doi:10.1097/AOG.0000000000002019
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。